Amneal Pharmaceuticals Files 8-K for Q3 2024 Results
Ticker: AMRX · Form: 8-K · Filed: Nov 8, 2024 · CIK: 1723128
Sentiment: neutral
Topics: financial-results, 8-k, sec-filing
Related Tickers: AMRX
TL;DR
Amneal dropped its Q3 2024 8-K, check financials now.
AI Summary
Amneal Pharmaceuticals, Inc. filed an 8-K on November 8, 2024, reporting on its results of operations and financial condition for the period ending September 30, 2024. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Bridgewater, NJ.
Why It Matters
This filing provides investors with crucial financial updates and operational results for Amneal Pharmaceuticals, impacting their investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing reporting past results, not indicating new or immediate risks.
Key Players & Entities
- Amneal Pharmaceuticals, Inc. (company) — Registrant
- November 8, 2024 (date) — Filing Date
- September 30, 2024 (date) — Reporting Period End Date
- Bridgewater, NJ (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Amneal Pharmaceuticals, Inc.'s Results of Operations and Financial Condition for the period ending September 30, 2024, along with Regulation FD Disclosures and Financial Statements and Exhibits.
When was this 8-K filed with the SEC?
This 8-K was filed with the SEC on November 8, 2024.
What is Amneal Pharmaceuticals, Inc.'s principal executive office address?
Amneal Pharmaceuticals, Inc.'s principal executive offices are located at 400 Crossing Blvd, Bridgewater, NJ 08807.
What is the Commission File Number for Amneal Pharmaceuticals, Inc.?
The Commission File Number for Amneal Pharmaceuticals, Inc. is 001-38485.
What is the fiscal year end for Amneal Pharmaceuticals, Inc.?
The fiscal year end for Amneal Pharmaceuticals, Inc. is December 31.
Filing Stats: 748 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-11-08 06:08:39
Key Financial Figures
- $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market
Filing Documents
- amrx-q32024x8k.htm (8-K) — 26KB
- amrx-q32024ex991.htm (EX-99.1) — 492KB
- amneala.jpg (GRAPHIC) — 3KB
- 0001723128-24-000037.txt ( ) — 523KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 8, 2024, Amneal Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the third quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. In accordance with General Instruction B.2 of Form 8-K, the information under Item 2.02 of this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the Securities Act), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
01 Regulation FD
Item 7.01 Regulation FD. Conference Call to Discuss Results Amneal will host a conference call and live webcast at 830 am Eastern Time on November 8, 2024, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company's website at httpsinvestors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 088741. A replay of the conference call will be posted shortly after the call and will be available for seven days. For a list of toll-free international numbers, visit this website httpswww.netroadshow.comeventsglobal-numbersconfId68226. The Company intends to publish an investor presentation that can be accessed at the Investors section of the Company's website, httpsinvestors.amneal.com, under the "Events Presentations" heading. In accordance with General Instruction B.2 of Form 8-K, the information referenced under Item 7.01 of this report is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished herewith Exhibit No. Description 99.1 Press release announcing results issued November 8, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date November 8, 2024 AMNEAL PHARMACEUTICALS, INC. By s Anastasios Konidaris Name Anastasios Konidaris Title Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)